The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40663700.
- Also identified by DOI 10.2337/db24-0861 and PMC identifier 12365420.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glucagon-like peptide-1 receptor agonists are promising therapies in treating various obesity-associated diseases; however, the mechanisms are convoluted with the benefits of weight loss. Dulaglutide has weight-independent therapeutic effects on the liver, reducing hepatic steatosis and improving liver function. Dulaglutide reduces de novo lipogenesis, lipid droplet stability, inflammation, and oxidative stress in the liver and lipolysis in adipose tissue. Weight loss may play an important role in glucagon-like peptide-1 receptor agonists' effect on decreasing coronary vascular disease risk.
Medical subject headings
- Fatty Liver
- Glucagon-Like Peptide-1 Receptor Agonists
- Glucagon-Like Peptides
- Hypoglycemic Agents
- Immunoglobulin Fc Fragments
- Obesity
- Recombinant Fusion Proteins